PRIDE试验中胶质母细胞瘤等毒性剂量递增放疗计划的模拟运行
PRIDE试验旨在评估75.0 Gy/30次联合贝伐珠单抗对MGMT启动子未甲基化胶质母细胞瘤的疗效。本研究通过模拟运行评估各中心计划质量与方案依从性,中位DSC为0.89-0.90,HD为12.1-17.0 mm,垂体与泪腺偏差最大,结论认为试验前需系统培训与持续监测。
要点
- 各中心按PRIDE方案完成计划,中位DSC为0.89-0.90,中位HD为12.1-17.0 mm。
- 垂体(中位DSC 0.37)和右泪腺(中位DSC 0.59)偏差最大。
- 结论认为试验前需系统培训反馈,并持续监测方案依从性。
核心结论
- 模拟运行揭示的偏差表明,放射肿瘤学临床试验开始前需进行系统培训并给予适当反馈,且研究全程需持续监测方案依从性。
研究设计与样本
- PRIDE试验(NOA-28; ARO-2024-01; AG-NRO-06; NCT05871021)的模拟运行,各拟参与研究中心按试验方案对同一患者病例进行放疗计划设计。
- 计划以DICOM文件上传至云平台,采用标准化清单、评分卡及Dice评分(DSC)和Hausdorff距离(HD)等指标分析计划质量与方案依从性。
主要发现
- PTV60、PTV60ex和PTV75的中位DSC分别为0.89、0.90和0.88,中位HD分别为17.0 mm、13.9 mm和12.1 mm。
- 标准计划PTV60体积范围为219.1-391.3 cc(中位261.9 cc),实验计划PTV75体积范围为71.5-142.7 cc(中位92.3 cc)。
- DSC偏差最大的结构为垂体(中位0.37,范围0.00-0.69)和右泪腺(中位0.59,范围0.42-0.78)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The PRIDE trial (NOA-28; ARO-2024-01; AG-NRO-06; NCT05871021) is designed to determine whether a dose escalation with 75.0 Gy in 30 fractions can enhance the median overall survival (OS) in patients with methylguanine methyltransferase (MGMT) promotor unmethylated glioblastoma compared to historical median OS rates, while being isotoxic to historical cohorts through the addition of concurrent bevacizumab (BEV). To ensure protocol-compliant irradiation planning with all study centers, a dummy run was planned and the plan quality was evaluated. METHODS: A suitable patient case was selected and the computed tomography (CT), magnetic resonance imaging (MRI) and O-(2-[18F]fluoroethyl)-L-tyrosine (FET) positron emission tomography (PET) contours were made available. Participants at the various intended study sites performed radiation planning according to the PRIDE clinical trial protocol. The treatment plans and dose grids were uploaded as Digital Imaging and Communications in Medicine (DICOM) files to a cloud-based platform. Plan quality and protocol adherence were analyzed using a standardized checklist, scorecards and indices such as Dice Score (DSC) and Hausdorff Distance (HD). RESULTS: Median DSC was 0.89, 0.90, 0.88 for PTV60, PTV60ex (planning target volume receiving 60.0 Gy for the standard and the experimental plan, respectively) and PTV75 (PTV receiving 75.0 Gy in the experimental plan), respectively. Median HD values were 17.0 mm, 13.9 mm and 12.1 mm, respectively. These differences were also evident in the volumes: The PTV60 had a volume range of 219.1-391.3 cc (median: 261.9 cc) for the standard plans, while the PTV75 volumes for the experimental plans ranged from 71.5-142.7 cc (median: 92.3 cc). The structures with the largest deviations in Dice score were the pituitary gland (median 0.37, range 0.00-0.69) and the right lacrimal gland (median 0.59, range 0.42-0.78). CONCLUSIONS: The deviations revealed the necessity of systematic trainings with appropriate feedback before the start of clinical trials in radiation oncology and the constant monitoring of protocol compliance throw-out the study. TRIAL REGISTRATION: NCT05871021.
引用
- Maier SH, Schönecker S, Anagnostatou V, et al. Dummy run for planning of isotoxic dose-escalated radiation therapy for glioblastoma used in the PRIDE trial (NOA-28; ARO-2024-01; AG-NRO-06). Clin Transl Radiat Oncol. 2024. PMID: 38765202. doi:10.1016/j.ctro.2024.100790
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。